Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Authors' conclusion
Alirocumab decreased LDL-C and LDL-apoB by increasing IDL- and LDL-apoB FCRs and decreasing LDL-apoB PR.
Study context
- Population
- Healthy humanscompleted
- Participants
- 18 participants
- Comparison
- Alirocumab vs placebo
- Outcome
- FCRs and PRs of apolipoprotein B100 (apoB) and apo(a)
- Follow-up
- End of each period
Methodological detailsplacebo-controlled, 2-period
- Placebo-controlled
- 2-period
Main finding
As reported in the abstract
- Ultracentrifugally isolated LDL-C reduction
- 55.1%
- Low-density lipoprotein (LDL)-apoB reduction
- 56.3%
- Plasma Lp(a) reduction
- 18.7%
- LDL-apoB FCR increase
- 80.4%
- LDL-apoB PR reduction
- 23.9%
- Intermediate-density lipoprotein (IDL)-apoB FCR increase
- 46.1%
- Conversion of IDL to LDL decrease
- 27.2%
- Apo(a) FCR tended to increase
- 24.6%
Further findings
Postprandial plasma TG and apoB48 (n = 10)
- No effect of alirocumab
Original publication
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation. Published 16 December 2016. doi:10.
Summarised from the published abstract; every number is checked against it